ED Eligibility 2026: Who Qualifies, How Verification Works, What Disqualifies

Erectile dysfunction has no single diagnostic test. Unlike hypertension (blood pressure cuff) or hypogonadism (lab-confirmed testosterone), ED is diagnosed primarily through clinical interview. The standard framework — endorsed by the American Urological Association, the Endocrine Society, and most insurance medical-necessity policies — requires the patient to report consistent inability to achieve or maintain an erection sufficient for satisfactory sexual function over a meaningful timeframe (typically 3+ months).

Telehealth providers use validated structured intake questionnaires — most commonly derivatives of the IIEF-5 (International Index of Erectile Function, 5-item version) or the SHIM (Sexual Health Inventory for Men). These are 5-question instruments that score ED severity from "no ED" to "severe ED" based on patient self-report. A score below the cutoff plus no contraindications produces an eligible patient.

Primary-care clinicians may use the same questionnaires or rely on a less structured interview. Urologists conducting workup for treatment-resistant ED may add penile Doppler ultrasound, nocturnal tumescence testing, or hormone panels — but these are diagnostic workup, not eligibility verification, and they're typically reserved for cases where first-line PDE5 inhibitors fail.

Five conditions disqualify a patient from PDE5 inhibitor therapy regardless of how mild their ED symptoms are. Each is non-negotiable across every legitimate provider:

1. Concurrent nitrate medication. Any organic nitrate prescription — nitroglycerin (sublingual, patch, ointment), isosorbide dinitrate, isosorbide mononitrate — combined with a PDE5 inhibitor produces life-threatening hypotension. The contraindication is absolute and applies even to as-needed nitrate use within the preceding 24 hours.
2. Recent cardiovascular event. Heart attack, stroke, or unstable angina in the past 6 months disqualifies. After 6 months, eligibility depends on cardiology clearance and current cardiac function.
3. Severe hepatic impairment. PDE5 inhibitors are metabolized in the liver. Severe cirrhosis or end-stage liver disease produces unpredictable plasma levels. Mild-to-moderate hepatic impairment can be managed with dose reduction.
4. Retinitis pigmentosa or recent NAION. Non-arteritic ischemic optic neuropathy is a rare but devastating ocular event that has been associated (causally unclear) with PDE5 use. Patients with prior NAION or hereditary retinal disease should avoid the medication class.
5. Blood pressure extremes. Resting systolic below 90 mmHg or above 170 mmHg, or diastolic below 50 mmHg or above 110 mmHg, disqualifies until BP is in the safe range.

Several medical conditions don't disqualify but require dose adjustment or specialist involvement:

• Alpha-blocker therapy (tamsulosin, terazosin) — start with the lowest PDE5 dose, separate doses by 4+ hours, and verify with prescribing clinician.
• End-stage renal disease — dose adjustment required; some clinicians prefer tadalafil over sildenafil due to different excretion profiles.
• Bleeding disorders or anticoagulation — clinically significant for injectable ED treatments (alprostadil), not typically for PDE5 inhibitors.
• Sickle-cell disease — increased priapism risk; treat under specialist supervision.
• QT-prolongation history — vardenafil specifically has slight QT effect and should be avoided; sildenafil and tadalafil are usually fine.
• Hearing loss or recent sudden change — discontinue PDE5 use and evaluate for SSNHL (sudden sensorineural hearing loss), a rare class effect.

Clinical eligibility criteria are identical between telehealth and in-person providers. The verification format differs:

• Async telehealth (BlueChew, Hims, Roman) — structured intake form, clinician reviews 4-24 hours later, prescription written if eligible. State law in most US states allows async for ED specifically; some require synchronous video for the first prescription.
• Sync telehealth (Sesame Care, Lemonaid Health, Push Health) — brief video visit with US-licensed clinician, similar intake content but with real-time conversation. Same-day completion typical.
• Primary-care visit — covered by insurance, more thorough physical exam and history, but takes 1-3 weeks to schedule. ED prescription typically written same visit if eligible.
• Urology consult — reserved for treatment-resistant cases or cases requiring workup beyond first-line PDE5 inhibitors. 4-8 week scheduling lead time typical.

For first-line ED treatment with sildenafil or tadalafil, async telehealth is the fastest, cheapest, and clinically equivalent path. Primary-care or urology becomes the right path when first-line treatment fails or when the patient prefers in-person care.

Medicare Part D excludes ED medications when prescribed for sexual dysfunction. CMS made this exclusion explicit in 2003 and reaffirmed it through multiple rule cycles. Medicare patients with ED pay cash, use a telehealth subscription, or access the medication when prescribed for a non-ED indication (tadalafil for BPH, sildenafil for pulmonary arterial hypertension).

Medicaid varies by state — most exclude ED medications mirroring the Medicare framework, a few cover under specific medical-necessity criteria.

VA coverage — the VA does cover ED medications for veterans diagnosed with service-connected conditions causing ED. Coverage is processed through the VA pharmacy benefit, which limits to specific quantities per month.

Tricare — generally excludes ED medications similar to Medicare.

For federal-plan enrollees, the practical path is cash-pay telehealth ($20-40/month generic sildenafil or tadalafil through BlueChew, Hims, Roman) — typically less expensive than navigating insurance carve-outs.